RUTHERFORD, N.J., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. The first study focuses on actionable diagnostic and prognostic information provided by CGI’s proprietary next-generation sequencing panel using renal cancer biopsies. The second study focuses on identification of somatic variants in metastatic clear cell renal cell carcinoma patients. Posters with results of both studies will be presented during the 2016 Genitourinary Cancers Symposium, on January 7-9, 2016 in San Francisco, CA.
Cancer Genetics will present its poster during the following session:
Saturday, January 9, 2016 Title: Clinical Utility of a Custom Next-Generation Sequencing Panel in the Diagnosis of Needle Biopsies from Renal Masses Poster Display: Saturday, January 9, 2016; 7:00 AM-7:55 AM and 11:30 AM-1:00PM Publication #: Abstract 528 Session: Poster Session C Location: Moscone West Building, Board E11 Presenter: Banumathy Gowrishankar, Principal Scientist, Cancer Genetics, Inc. Collaborators: Memorial Sloan-Kettering Cancer Center
Title: Metastasis-Associated Mutations in Clear Cell Renal Cell Carcinoma Poster Display: Saturday, January 9, 2016; 7:00 AM-7:55 AM and 11:30 AM-1:00PM Publication #: Abstract 600 Session: Poster Session C Location: Moscone West Building, Board H19 Presenter: Banumathy Gowrishankar, Principal Scientist, Cancer Genetics, Inc. Collaborators: Memorial Sloan-Kettering Cancer Center & Weill Cornell Medical College
The abstracts can be viewed online through the 2016 Genitourinary Cancers Symposium website.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in personalized cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow us: Internet: http://www.cancergenetics.com Twitter: @Cancer_Genetics Facebook: www.facebook.com/CancerGenetics Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Media Contact: Cancer Genetics, Inc. Marie-Agnes Patrone-Michellod, PhD. Tel: 201.528.9200 Email: marie.michellod@cgix.com
